CRISPR Therapeutics AG (CRSP): Total Assets
$2.27B
As of 2025-12-31
$2.65B
As of 2026-06-30
+0.3%
3-year compound annual growth
+4.4%
5-year compound annual growth
+30.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.27B | +1.0% | 2026-02-12, Balance as of period end |
| 2024-12-31 | $2.24B | +0.6% | 2026-02-12, Balance as of period end |
| 2023-12-31 | $2.23B | -0.6% | 2025-02-11, Balance as of period end |
| 2022-12-31 | $2.24B | -18.5% | 2024-02-21, Balance as of period end |
| 2021-12-31 | $2.75B | +50.5% | 2023-02-21, Balance as of period end |
| 2020-12-31 | $1.83B | +71.4% | 2022-02-15, Balance as of period end |
| 2019-12-31 | $1.07B | +118.1% | 2021-02-16, Balance as of period end |
| 2018-12-31 | $489.02M | +80.2% | 2020-02-12, Balance as of period end |
| 2017-12-31 | $271.35M | -21.3% | 2019-02-25, Balance as of period end |
| 2016-12-31 | $344.96M | +116.4% | 2018-03-08, Balance as of period end |
| 2015-12-31 | $159.42M | n/a | 2017-03-10, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | $2.27B | +1.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $98.73M | +103.7% |
| Dyadic International Inc (DYAI) | 2025-12-31 | $9.95M | +0.2% |
| CG Oncology, Inc. (CGON) | 2025-12-31 | $791.59M | +4.9% |
| Ocugen, Inc. (OCGN) | 2025-12-31 | $43.52M | -47.2% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $342.73M | +15.2% |
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | $1.53M | -7.1% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $88.53M | +26.3% |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | $233.72M | +256.0% |
Compare CRSP, SRZN, DYAI, CGON side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗